COVID-19-associated seizure

Jump to navigation Jump to search

COVID-19 Microchapters

Home

Long COVID

Frequently Asked Outpatient Questions

Frequently Asked Inpatient Questions

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating COVID-19 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Vaccines

Secondary Prevention

Future or Investigational Therapies

Ongoing Clinical Trials

Case Studies

Case #1

COVID-19-associated seizure On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of COVID-19-associated seizure

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on COVID-19-associated seizure

CDC on COVID-19-associated seizure

COVID-19-associated seizure in the news

Blogs on COVID-19-associated seizure

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for COVID-19-associated seizure

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Safakhah, MD[2]

Synonyms and keywords:

Overview

Coronaviruses impacts are not always restricted to respiratory system and they have potential for neuroinvasion under specific circumstances. Neurological manifestations such as dizziness,headache ,anosmia as well as case reports with encephalitis ,stroke,epileptic seizures associated with covid-19, have been reported.

Historical Perspective

  • two male patients, non-epileptic were hospitalised with covid-19 signs and symptoms, March 2020 ,Ohio, U.S.A. During their hospital stay they developed encephalopathy and seizures, controlled by levetiracetam
  • A women with the past medical history of seizure following herpetic encephalitis ,presented with a sudden focal myoclonus and positive test for covid 19 in Italy, 23rd of april 2020.[1]
  • Also, a cohort multicentre study was done in China, April 2020, demonstrating that COVID 19 doesn't increase the risk of symptomatic seizure in patients hospitalized with the acute respiratory phase of COVID 19.Although ,some seizure-like reactions are seen because of acute reaction to stress or hypocalcemia .[2]

Classification

There isn't any established classification for covid-19 associated seizure.

Pathophysiology

  • Neurological complications caused by COVID-19 are through direct or indirect pathways. This includes hematogenous pathway, neuronal retrograde dissemination through olfactory bulb, entry into to glial cells and neurons via ACE2 receptor and impairment of gas exchange in lungs leading to anemia, hence increasing anaerobic metabolites in brain resulting in cellular and interstitial edema [3]
  • Seizures in a patient with COVID-19 may be due to primary virus infection or due to reactivation of the latent virus.
  • Infiltration of the brain tissue by the virus and subsequent production of toxins by the virus is one of the several mechanisms that can cause seizures in a COVID-19 patient. [4]
  • Production of inflammatory mediators by the brain may also trigger seizures.
  • Inflammatory cytokines that are released as a result of inflammatory cascade provoked by COVID-19 include interleukin 2,6,7, and 10, TNF-α and granulocyte colony-stimulating factor. Consequently, activation of glutamate receptors by the cytokines causes neuronal hyperexcitability and development of seizures. [4]
Pathophysiology

Causes

The aetiology of seizure regardless whether it is covid-19 or not ,is divided into two categories:

  • 'Provoked seizures : these seizures usually have a temporary trigger such as CNS infection,electrolytes disturbance, withdrawal syndrome,sepsis ,fever, sleep deprivation and stroke.
  • Unprovoked seizures: In this catrgory ,there isn't any obvious cause or precipitating factor .[5]

Differentiating COVID-19-associated seizure from other Diseases

Apart from the viral cause of the seizure, the differential diagnosis for this disease is usually based on the presenting symptoms as below:

Epidemiology and Demographics

By now there isn't any sufficient evidence for demographic and epidemiologic data about covid- 19 associated seizure.

Risk Factors

There are no established risk factors for covid-19 associated seizure.

Screening

There is insufficient evidence to recommend routine screening for covid-19 associated seizure.

Natural History, Complications, and Prognosis

The global case fatality rate is currently estimated to be 4.6% according to WHO , 9th,June.[7] Also neurological complications of covid-19 .The covid-19 fatality rate depends on several factors such as:

  • patient demographics
  • availability of health care
  • test limitation

Also , the more comorbidities the patient has ,the poorer covid-19 clinical output. Some of the prognostic factor of covid-19 are listed as below:

  • Above 65 years old
  • smoking
  • male sex
  • elevated inflammatory markers
  • elevated D-Dimer
  • elevated interleukin 6
  • thrombocytopenia
  • high neutrophil to lymphocyte ratio
  • higher acute physiology and chronic health evaluation score.[8]

Diagnosis

Diagnostic Study of Choice

The diagnosis of COVID-19-associated seizure is made through:

  • Electroencephalogram (EEG, brain waive activity)[9].

Other diagnostic tests include:

History

Symptoms

Physical Examination

Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].

OR

Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].

OR

The presence of [finding(s)] on physical examination is diagnostic of [disease name].

OR

The presence of [finding(s)] on physical examination is highly suggestive of [disease name].

Laboratory Findings

Postictal levels of the following may be elevated in a patient with seizures:

  • Prolactin (within 20 minutes after a convulsive event)
  • Lactate (within 1 to 2 hours)
  • Ammonia (within several hours)
  • Creatine kinase (especially 24 to 48 hours postictally)
  • To view the laboratory findings on COVID-19, click here.

Electrocardiogram

  • There are no typical ECG findings associated with seizures in a COVID-19 patient.
  • To view the electrocardiogram findings on COVID-19, click here.

X-ray

  • There are no x-ray findings associated with COVID-19 associated seizure.
  • * To view the x-ray finidings on COVID-19, click here.

Echocardiography or Ultrasound

CT scan

  • CT brain may show structural lesions but majority of patients will show nothing.
  • To view the CT scan findings on COVID-19, click here.

MRI

  • MRI brain may show structural lesions but majority of patients will show nothing.
  • To view the MRI findings on COVID-19, click here.

Other Imaging Findings

  • There are no other imaging findings associated with seizure related to COVID-19.
  • To view other imaging findings on COVID-19, click here.


Other Diagnostic Studies

  • To view other diagnostic studies for COVID-19, click here.

Treatment

Medical Therapy

  • Development of seizures in a COVID-19 patient requires urgent treatment.
  • After the cause of seizure is determined, medical therapy should be aimed at treating the cause immediately (for example, hypoxia, fever, metabolic imbalance).
  • Anti-seizure medication (ASM) is often necessary.
  • For a single seizure less than 5 min rescue treatment with benzodiazepine is not needed. Intravenous ASM are used with caution in COVID-19 patients due to the adverse effects (e.g., Phenytoin, Phenobarbital and Lacosamide in respiratory and cardiac problems) and drug interactions (e.g., Carbamazepine, Phenytoin, Phenobarbital and Valproic acid). [13]
  • Brivaracetam and Levetiracetam have less adverse effects and drug interactions. [13]
  • In patients with more than one seizure (either shorter or longer than 5 min) and in status epilepticus rescue treatment with benzodiazepines in addition to ASM is needed. [13]

Surgery

Surgical intervention is not recommended for the management of COVID-19 associated seizure.


Primary Prevention

There are no established measures for the primary prevention of [disease name].

OR

There are no available vaccines against [disease name].

OR

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

OR

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

References

  1. {{https://www.seizure-journal.com/article/S1059-1311(20)30115-1/fulltext}}
  2. {{https://onlinelibrary.wiley.com/doi/full/10.1111/epi.16524}}
  3. {{https://pubmed.ncbi.nlm.nih.gov/32458193/}}
  4. 4.0 4.1 Karimi, Narges; Sharifi Razavi, Athena; Rouhani, Nima (2020). "Frequent Convulsive Seizures in an Adult Patient with COVID-19: A Case Report". Iranian Red Crescent Medical Journal. 22 (3). doi:10.5812/ircmj.102828. ISSN 2074-1804.
  5. {{https://www.ncbi.nlm.nih.gov/books/NBK430765/}}
  6. {{https://www.nice.org.uk/guidance/CG20/documents/appendix-a-a-differential-diagnosis-first-consultation2}}
  7. Template:Https://bestpractice.bmj.com/topics/en-gb/3000168/prognosis
  8. Template:Https://bestpractice.bmj.com/topics/en-gb/3000168/prognosis
  9. Haines S, Caccamo A, Chan F, Galaso G, Catinchi A, Gupta PK (2020). "Practical Considerations When Performing Neurodiagnostic Studies on Patients with COVID-19 and Other Highly Virulent Diseases". Neurodiagn J. 60 (2): 78–95. doi:10.1080/21646821.2020.1756132. PMC 7212538 Check |pmc= value (help). PMID 32374647 Check |pmid= value (help).
  10. Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM (2018). "Neurologic Alterations Due to Respiratory Virus Infections". Front Cell Neurosci. 12: 386. doi:10.3389/fncel.2018.00386. PMC 6212673. PMID 30416428.
  11. Li YC, Bai WZ, Hashikawa T (2020). "The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients". J Med Virol. 92 (6): 552–555. doi:10.1002/jmv.25728. PMC 7228394 Check |pmc= value (help). PMID 32104915 Check |pmid= value (help).
  12. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K (2020). "Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review". Clin Neurol Neurosurg. 194: 105921. doi:10.1016/j.clineuro.2020.105921. PMC 7227498 Check |pmc= value (help). PMID 32422545 Check |pmid= value (help).
  13. 13.0 13.1 13.2 Asadi-Pooya AA (July 2020). "Seizures associated with coronavirus infections". Seizure. 79: 49–52. doi:10.1016/j.seizure.2020.05.005. PMC 7212943 Check |pmc= value (help). PMID 32416567 Check |pmid= value (help).


Template:WikiDoc Sources